# H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer

> **NCT01991340** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 657 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01991340
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 657 (ACTUAL)
- **Last updated:** 2013-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01991340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01991340, "H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01991340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*